







Item 8.01. Other Events.

On February 28, 2019, TG Therapeutics, Inc. (the “Company”) issued a press release announcing data from the UNITY-NHL Phase 2b pivotal trial evaluating umbralisib in patients with relapsed/refractory marginal zone lymphoma. A copy of the press release is being filed as Exhibit 99.1 and incorporated in this Item by reference.

Item 9.01 Financial Statements And Exhibits.

(d) Exhibits.

99.1 Press Release, dated February 28, 2019



SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

TG Therapeutics, Inc.  
(Registrant)

Date: February 28, 2019

By: /s/ Sean A. Power  
Sean A. Power  
Chief Financial Officer